Literature DB >> 25121001

Comparative Study of Lithotripsy and PCNL for 11-15 mm Lower Caliceal Calculi In Community Health Hospital.

Narendra Haribhau Wankhade1, Jayant Gadekar2, Babaji B Shinde3, Julie Anand Tatte4.   

Abstract

BACKGROUND AND
PURPOSE: Percutaneous Nephrolithotomy (PCNL) is not a popular procedure in smaller sized calculi due to its invasive nature, complications and need for anesthesia. Small sized lower caliceal calculi are generally treated by ESWL but have significantly less clearance rate in spite of several sittings. Here we want to study the efficacy and safe of both procedures in 11 to 15 mm lower caliceal calculi.
MATERIALS AND METHODS: We present comparative study of lithotripsy and PCNL in 11-15 mm lower caliceal calculi in our hospital. Total 156 patients were studied 78 underwent lithotripsy and 78 underwent PCNL. We compared results in the form of clearance rate, the number of settings needed, hospital stay, need for anesthesia, blood transfusion rate, chest complication, the incidence of sepsis, the need for another procedure, need for stenting in either group.
RESULTS: We found a 67.95% clearance rate in SWL group and 97.43% clearance rate in PCNL group. Hospital stay was minimum in SWL group and was 46 hours in PCNL group. The procedure time was 42 minutes in PCNL and it was 114 mins in SWL (considering all settings). The rest of the complications like chest complication, sepsis and bleeding were negligible due to the small size of calculi.
CONCLUSION: In a small sized LPC calculi, PCNL is gaining increased popularity due to lower complication and high safety and complete clearance rate. It is wide accepted by society as the patient is totally stone free at the end of the procedure. SWL is less invasive but less effective and has given significant discomfort to patients.

Entities:  

Keywords:  LPC calculi; PCNL; SWL

Year:  2014        PMID: 25121001      PMCID: PMC4129250          DOI: 10.7860/JCDR/2014/6704.4502

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  14 in total

1.  Management of lower-pole caliceal stones.

Authors:  Glenn S Gerber
Journal:  J Endourol       Date:  2003-09       Impact factor: 2.942

2.  Percutaneous nephrolithotomy for the treatment of lower pole renal calculi.

Authors:  Reem Al-Bareeq; John D Denstedt
Journal:  Can Urol Assoc J       Date:  2008-12       Impact factor: 1.862

3.  Treating lower pole renal stones: in defence of shock wave lithotripsy.

Authors:  John Honey
Journal:  Can Urol Assoc J       Date:  2008-12       Impact factor: 1.862

4.  Predictive factors of lower calyceal stone clearance after Extracorporeal Shockwave Lithotripsy (ESWL): a focus on the infundibulopelvic anatomy.

Authors:  Islam A Ghoneim; Ali M Ziada; Seif Eldin Elkatib
Journal:  Eur Urol       Date:  2005-03-09       Impact factor: 20.096

5.  Extracorporeal shock wave lithotripsy for lower caliceal calculi.

Authors:  B Küpeli; H Biri; Z Sinik; K Karaca; A Tuncayengin; U Karaoğlan; I Bozkirli
Journal:  Eur Urol       Date:  1998-09       Impact factor: 20.096

6.  [Predictive factors of successful treatment of lower caliceal calculi with Edap LT02 extracorporeal lithotripsy].

Authors:  M Nouri; M Tligui; F Haab; A Flahaut; B Gattegno; P Thibault
Journal:  Prog Urol       Date:  2000-09       Impact factor: 0.915

7.  Infundibulopelvic anatomy and clearance of inferior caliceal calculi with shock wave lithotripsy.

Authors:  N P Gupta; D V Singh; A K Hemal; S Mandal
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Impact of Residual Fragments following Endourological Treatments in Renal Stones.

Authors:  Cenk Acar; Cag Cal
Journal:  Adv Urol       Date:  2012-07-05

9.  Percutaneous nephrolithotomy for 1-2 cm lower-pole renal calculi.

Authors:  Percy Jal Chibber
Journal:  Indian J Urol       Date:  2008-10

10.  Extracorporeal shockwave lithotripsy for lower pole calculi smaller than one centimeter.

Authors:  Christian Chaussy; Thorsten Bergsdorf
Journal:  Indian J Urol       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.